News Related to TLX101-TX

Related coverage linked through entity extraction aliases.

Telix Pharmaceuticals Submits Brain Cancer Imaging Agent TLX101-Px for Regulatory Approval

Mar 16, 2026

Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.

Telix Submits European Marketing Authorization for Brain Cancer Imaging Agent TLX101-Px

Feb 18, 2026

Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.